Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 1.49
AVNR's Cash to Debt is ranked higher than
64% of the 750 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.39 vs. AVNR: 1.49 )
AVNR' s 10-Year Cash to Debt Range
Min: 0.32   Max: No Debt
Current: 1.49

Equity to Asset 0.15
AVNR's Equity to Asset is ranked lower than
59% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.60 vs. AVNR: 0.15 )
AVNR' s 10-Year Equity to Asset Range
Min: -0.16   Max: 0.98
Current: 0.15

-0.16
0.98
F-Score: 3
Z-Score: -8.00
M-Score: -3.03
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -94.77
AVNR's Operating margin (%) is ranked lower than
54% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.34 vs. AVNR: -94.77 )
AVNR' s 10-Year Operating margin (%) Range
Min: -1373.1   Max: 35.08
Current: -94.77

-1373.1
35.08
Net-margin (%) -100.15
AVNR's Net-margin (%) is ranked lower than
55% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.48 vs. AVNR: -100.15 )
AVNR' s 10-Year Net-margin (%) Range
Min: -1389.34   Max: 1.84
Current: -100.15

-1389.34
1.84
ROE (%) -408.60
AVNR's ROE (%) is ranked lower than
61% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. AVNR: -408.60 )
AVNR' s 10-Year ROE (%) Range
Min: -8600   Max: 0.97
Current: -408.6

-8600
0.97
ROA (%) -99.21
AVNR's ROA (%) is ranked lower than
59% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.94 vs. AVNR: -99.21 )
AVNR' s 10-Year ROA (%) Range
Min: -477.78   Max: 0.86
Current: -99.21

-477.78
0.86
ROC (Joel Greenblatt) (%) -4483.80
AVNR's ROC (Joel Greenblatt) (%) is ranked lower than
58% of the 732 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.50 vs. AVNR: -4483.80 )
AVNR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -7049.84   Max: 342.25
Current: -4483.8

-7049.84
342.25
Revenue Growth (%) 160.40
AVNR's Revenue Growth (%) is ranked higher than
99% of the 552 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. AVNR: 160.40 )
AVNR' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 160.4
Current: 160.4

0
160.4
EBITDA Growth (%) 18.60
AVNR's EBITDA Growth (%) is ranked higher than
82% of the 507 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. AVNR: 18.60 )
AVNR' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 223.2
Current: 18.6

0
223.2
EPS Growth (%) 20.90
AVNR's EPS Growth (%) is ranked higher than
83% of the 510 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. AVNR: 20.90 )
AVNR' s 10-Year EPS Growth (%) Range
Min: -67.9   Max: 238.4
Current: 20.9

-67.9
238.4
» AVNR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2012

AVNR Guru Trades in Q4 2012

Steven Cohen 827,300 sh (+106.05%)
» More
Q1 2013

AVNR Guru Trades in Q1 2013

Steven Cohen Sold Out
» More
Q3 2013

AVNR Guru Trades in Q3 2013

Steven Cohen 14,500 sh (New)
Paul Tudor Jones 42,100 sh (New)
» More
Q4 2013

AVNR Guru Trades in Q4 2013

Steven Cohen 22,061 sh (+52.14%)
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with AVNR



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 57.67
AVNR's P/B is ranked lower than
77% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.84 vs. AVNR: 57.67 )
AVNR' s 10-Year P/B Range
Min: 0.78   Max: 202.67
Current: 57.67

0.78
202.67
P/S 5.77
AVNR's P/S is ranked lower than
66% of the 722 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.99 vs. AVNR: 5.77 )
AVNR' s 10-Year P/S Range
Min: 2.23   Max: 116.75
Current: 5.77

2.23
116.75

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 57.67
AVNR's Price/Tangible Book is ranked lower than
87% of the 629 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.10 vs. AVNR: 57.67 )
AVNR' s 10-Year Price/Tangible Book Range
Min: 1.32   Max: 90.91
Current: 57.67

1.32
90.91
Price/Median PS Value 0.22
AVNR's Price/Median PS Value is ranked higher than
98% of the 665 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.10 vs. AVNR: 0.22 )
AVNR' s 10-Year Price/Median PS Value Range
Min: 0.15   Max: 55.36
Current: 0.22

0.15
55.36
Earnings Yield (Greenblatt) 0.60
AVNR's Earnings Yield (Greenblatt) is ranked lower than
69% of the 595 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. AVNR: 0.60 )
AVNR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.6   Max: 3.8
Current: 0.6

0.6
3.8
Forward Rate of Return (Yacktman) -4.38
AVNR's Forward Rate of Return (Yacktman) is ranked higher than
58% of the 532 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.45 vs. AVNR: -4.38 )
AVNR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -1.8   Max: -0.5
Current: -4.38

-1.8
-0.5

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:AV2B.Germany
Avanir Pharmaceuticals was incorporated in California in August 1988 and was reincorporated in Delaware in March 2009. The Company is a pharmaceutical company focused on acquiring, developing and commercializing novel therapeutic products for the treatment of central nervous system disorders. The Company commenced promotion of NUEDEXTA in the United States in February 2011. The Company is also studying AVP-923 for use in different types of neuropathic pain. NUEDEXTA is the first and only FDA-approved treatment for pseudobulbar affect. NUEDEXTA is an innovative combination of two components: dextromethorphan hydrobromide, the ingredient that is harmacologically active in the central nervous system, and quinidine sulfate, a metabolic inhibitor enabling dextromethorphan to reach therapeutic plasma concentrations. The Company currently markets NUEDEXTA to approximately 10,000 physicians and other healthcare providers who specialize in psychiatry, neurology or geriatric medicine and practice in outpatient or long-term care settings. NUEDEXTA may face competition from several products: Antidepressants, including Prozac, Celexa, Zoloft, Paxil, Elavil and Pamelor and others; Atypical antipsychotic agents, including Zyprexa, Risperdal, Seroquel, Abilify, Geodon and others; and Miscellaneous agents, including Symmetrel, Lithium and others. The Company is subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substance Control Act, the Export Control Act and other present and future laws of general application.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide